Inhaled delivery of biotherapeutic active pharmaceutical ingredients (APIs) is of growing importance in the pharmaceutical pipeline. When formulated as dry powders, local delivery of biologic molecules is possible without the need for cold-chain storage, facilitating a patient-centric treatment approach. In this webinar, the use of spray drying to manufacture dry powder formulations of protein APIs will be discussed. A case study will also be presented, in which an inhaled formulation of the antibody bevacizumab demonstrated 24-month stability at 25°C.

Key Learning Objectives

  • Understand formulation approaches for dry powder inhalers (DPIs) with protein-based APIs
  • Describe the key attributes of a room-temperature stable spray-dried powder of a biotherapeutic API
  • Appreciate the patient centricity of DPI formulations for lung delivery
You may also be interested in:
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center